Initial treatment of hypertension

New England Journal of Medicine

Volumn 348, Issue 7, 2003, Pages 610-617

  August, Phyllis ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOSARTAN; THIAZIDE DIURETIC AGENT;

ANAMNESIS; ANGIONEUROTIC EDEMA; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BODY WEIGHT; BRADYCARDIA; BRONCHOSPASM; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL FEATURE; CLINICAL TRIAL; COUGHING; DISEASE COURSE; DOSE RESPONSE; DROWSINESS; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG INDICATION; EDEMA; EXERCISE TOLERANCE; FATIGUE; FLUSHING; GINGIVA HYPERPLASIA; GLUCOSE INTOLERANCE; HEADACHE; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; HYPOKALEMIA; HYPONATREMIA; IMPOTENCE; INSOMNIA; ISCHEMIC HEART DISEASE; LEUKOPENIA; LIFESTYLE; MEDICAL DECISION MAKING; MUSCLE WEAKNESS; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PERIPHERAL ISCHEMIA; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RASH; SODIUM RESTRICTION; TASTE DISORDER; TREATMENT PLANNING;

ANTIHYPERTENSIVE AGENTS; DIET, REDUCING; DIET, SODIUM-RESTRICTED; HUMANS; HYPERTENSION; LIFE STYLE; MALE; MIDDLE AGED; OBESITY; PRACTICE GUIDELINES; SMOKING CESSATION;

EID: 0037434553     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMcp010357     Document Type: Article

References (46)

1. Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment and control of hypertension in the adult US population: data from the health examination surveys, 1960 to 1991. Hypertension 1995;26:60-9. [Erratum, Hypertension 1996;27:1192.]
2. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-46. [Erratum, Arch Intern Med 1998;158:573.]
3. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998;352:1347-51.
4. Kannel WB. Elevated systolic blood pressure as a cardiovascular risk factor. Am J Cardiology 2000;15:251-5.
5. Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000;355:865-72. [Erratum, Lancet 2001;357:724.]
6. Stamler J. Blood pressure and high blood pressure: aspects of risk. Hypertension 1991; 18:Suppl I:I-95-I-107.
7. Perloff D, Grim CM, Flack J, et al. Human blood pressure determination by sphygmomanometry. Circulation 1993;88:2460-70.
8. Pickering TG. Recommendations for the use ofhome (self) and ambulatory blood pressure monitoring. Am J Hypertens 1996;9:1-11.
9. Kannel WB. Potency of vascular risk factors as the basis for antihypertensive therapy. Eur Heart J 1992;13:Suppl G:34-42.
10. Dustan HP, Schneckloth RE, Corcoran AC, Page IH. The effectiveness oflong-term treatment of malignant hypertension. Circulation 1958;18:644-51.
11. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary disease. 2. Short-term reductions in blood pressure: overview ofrandomized drug trials in their epidemiological context. Lancet 1990;335:827-38.
12. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA 1997;277:739-45.
13. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 1997;336:1117-24.
14. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure ofreduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001;344:3-10.
15. Midgley JP, Matthew AG, Greenwood CM, Logan AG. Effect of reduced dietary sodium on blood pressure: a meta-analysis of randomized controlled trials. JAMA 1996;275:1590-7.
16. Cutler JA, Follmann D, Allender PS. Randomized trials of sodium reduction: an overview. Am J Clin Nutr 1997;65:Suppl:643S-651S.
17. Alderman MH, Madhavan S, Cohen H. Low urinary sodium is associated with greater risk ofmyocardial infarction among treated hypertensive men. Hypertension 1995;25:1144-52.
18. Kumanyika SK, Cutler JA. Dietary sodium reduction: is there cause for concern? J Am Coll Nutr 1997;16:192-203.
19. Appel LJ, Espeland MA, Easter L, Wilson AC, Folmar S, Lacy CR. Effects of reduced sodium intake on hypertension control in older individuals: results from the Trial of Nonpharmacologic Interventions in the Elderly (TONE). Arch Intern Med 2001;161:685-93.
20. Neaton JD, Grimm RHJ, Prineas RJ, et al. Treatment of Mild Hypertension Study: final results. JAMA 1993;270:713-24.
21. Gritara RH Jr, Grandits GA, Cutler JA, et al. Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study. Arch Intern Med 1997;157:638-48.
22. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351:1755-62.
23. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317:703-13. [Erratum, BMJ 1999;318:29.
24. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-64.
25. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med 1993;328: 914-21. [Erratum, N Engl J Med 1994;330:1689.
26. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results ofprospectively designed overviews of randomised trials. Lancet 2000;356:1955-64.
27. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53. [Errata, N Engl J Med 2000;342:748,1376.
28. Staessen JA, Wang JG, Thij L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001;358:1305-15. [Erratum, Lancet 2002;359:360.]
29. Estado RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect ofnisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645-52.
30. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-6.
31. DahlofB, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
32. Pahor M, Psaty BM, Alderman MH, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 2000;356:1949-54.
33. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
34. Wing LMH, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for the treatment of hypertension in the elderly. N Engl J Med 2003;348:583-92.
35. Lewis EJ, Hunsicker LG, Bain KP, Rhode RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62. [Erratum, N Engl J Med 1993;330:152.]
36. Hostetter TH. Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med 2001;345:910-2.
37. Furberg CD, Psaty BM. Should calcium antagonists be first-line agents in the treatment of cardiovascular disease? The public health perspective. Cardiovasc Drugs Ther 1996;10:463-6.
38. Saunders E, Weir MK, Kong BW, et al. A comparison of the efficacy and safety of a B-blocker, a calcium-channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990;150:1707-13.
39. Neutel JM, Smith DHG, Weber MA. Low dose combination therapy vs. high dose monotherapy in the management of hypertension. J Clin Hypertens (Greenwich) 1999;1:79-86.
40. Prisant LM, Weir MR, Papademetriou V, et al. Low-dose drug combination therapy: an alternative first-line approach to hypertension treatment. Am Heart J 1995;130:359-66.
41. Guidelines Subcommittee of the World Health Organization-International Society of Hypertension (WHO-ISH). 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999;17:151-83.
42. Ramsay LE, Williams B, Johnston GD, et al. British Hypertension Society guidelines for hypertension management 1999: summary. BMJ 1999;319:630-5.
43. Jackson R, Barham P, Bills J, et al. Management of raised blood pressure in New Zealand. BMJ 1993;307:107-10.
44. Hoes AW, Grobbee DE, Lubsen J. Does drug treatment improve survival? Reconciling the trials in mild-to-moderate hypertension. J Hypertens 1995;13:805-11.
45. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001;345:1291-7.
46. Mann SJ, Blumenfeld JD, Laragh JH. Issues, goals, and guidelines for choosing first-line and combination antihypertensive drug therapy. In: Laragh JH, Brenner BM, eds. Hypertension: pathophysiology, diagnosis, and management, 2nd ed. Vol. 2. New York: Raven Press, 1995:2531-42.